A phase II study of gilteritinib plus azacitidine in unfit patients with newly diagnosed FLT3-ITD AML with primary endpoint of OS is currently accruing (NCT02752035) with interim results of secondary endpoints demonstrating CR and ORR rates of 67 and 80%, respectively (89). The gene discussed is FLT3; the disease is acute myeloid leukemia.